Spondyloarthritis & psoriatic arthritis
Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with psoriatic arthritis (PsA) and inadequate response to TNFi: post hoc analysis of COSMOS
Authors' conclusion
Guselkumab treatment provided substantial benefits across multiple disease domains, with increasing proportions of patients achieving LDA/remission over 1 year, highlighting the effectiveness of guselkumab despite previous inadequate response to TNFi.
Study context
- Population
- Adults with active PsA and inadequate response to 1 or 2 TNFi (TNFi-IR)
- Participants
- 285 adults
- Comparison
- Guselkumab 100 mg vs placebo
- Primary endpoint
- Composite index endpoints of LDA and remission (DAPSA, DAS28, PsARC, PASDAS, GRACE, mCPDAI, MDA, very low disease activity (VLDA))
- Follow-up
- W24
Methodological detailsPhase IIIb, placebo crossover to guselkumab at W24, non-responder imputation through W48, treatment failure rules through W24
- Phase IIIb
- Placebo crossover to guselkumab at W24
- Non-responder imputation through W48
- Treatment failure rules through W24
Primary result
As reported in the abstract
Composite index endpoints at W24
Low disease activity (LDA), Guselkumab vs Placebo
14.8-52.4% vs 3.1-28.1%
Remission, Guselkumab vs Placebo
3.7-5.3% vs 0.0-2.1%
Further findings
- LDA, minimal disease activity (MDA) and Psoriatic Arthritis Response Criteria (PsARC) response in guselkumab-randomised patients · W48
- 44.4% · DAPSA LDA · DAS28 LDA 47.8% · Psoriatic Arthritis Disease Activity Score (PASDAS) LDA 34.4% · GRACE LDA 33.3% · modified Composite Psoriatic Disease Activity Index (mCPDAI) LDA 40.2% · MDA 27.0% · PsARC response 64.0%
LDA, MDA and PsARC response in guselkumab-randomised patients · W48
- Placebo→guselkumab crossover: W48 response rates similar to guselkumab-randomised
Original publication
Multi-domain effectiveness of guselkumab evaluated via composite indices through 1 year in patients with PsA and inadequate response to TNFi: post hoc analysis of COSMOS. Rheumatology (Oxford). Published 22 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →